Latest Articles

Publication Date
All News Scientific
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer - Targeted Oncology

Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer Targeted Oncology

Published: Jan. 22, 2026, 4:02 p.m.
Read Full Article
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer - targetedonc.com

Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer targetedonc.com

Published: Jan. 22, 2026, 4:02 p.m.
Read Full Article
Ashiana Ispat Limited Price Targets Raised After Rebound - July 2025 Snapshot & Daily Volume Surge Signals - bollywoodhelpline.com

Ashiana Ispat Limited Price Targets Raised After Rebound - July 2025 Snapshot & Daily Volume Surge Signals bollywoodhelpline.com

Published: Jan. 18, 2026, 7:26 p.m.
Read Full Article
Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer? - Oncology Nursing News

Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer? Oncology Nursing News

Published: Jan. 14, 2026, 7:32 p.m.
Read Full Article
Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity - TipRanks

Natera Targets Endometrial Cancer With New Signatera Trial, Expanding Its MRD Opportunity TipRanks

Published: Jan. 14, 2026, 4:33 p.m.
Read Full Article
Novel Small Molecule Inhibitors Show Efficacy in Endometrial Cancer - Targeted Oncology

Novel Small Molecule Inhibitors Show Efficacy in Endometrial Cancer Targeted Oncology

Published: Jan. 11, 2026, 4:14 p.m.
Read Full Article
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com UK

Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com UK

Published: Jan. 9, 2026, 2:25 p.m.
Read Full Article
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com

Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com

Published: Jan. 9, 2026, 1:59 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 9, 2026, 6:18 a.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - The Manila Times

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 8, 2026, 12:53 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!